PCSK9 and hyperlipidemia: Although a longer-term study is yet to be initiated, the similarities in efficacy shared by alirocumab and NYX-PCSK9i in the same mouse model of hyperlipidemia add weight to NYX-PCSK9i′s viability as an alternative to monoclonal PCSK9 antibodies in the clinic.